Business
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious
About this update from Invivyd, Inc.
[{"type":"text","content":"WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced the upcoming presentations of pemivibart data from its Phase 1 and Phase 3 clinical trials at IDWeek 2024. The conference is being held in Los Angeles, October 16-19, 2024. Invivyd will be presenting the following oral and poster presentations: TitlePresenting AuthorPresentation TimingOral Presentation: Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating Pemivibart Anna Holmes, Ph.D., Principal Clinical ScientistOctober 17 (11:18-11:30am PT/2:18 -2:30pm ET)Poster: Results from a Phase 1 First in Human Study of Pemivibart: An Extended Half-Life Monoclonal Antibody (mAb)Amanda Copans, PharmD, Vice President, Medical AffairsOctober 19 (12:15 – 1:30pm PT/3:15 – 4:30pm ET)Poster: Pharmacokinetics (PK) and Serum Virus Neutralizing Antibody (sVNA) Titers Following the 2nd dose of Pemivibart in the Phase 3 CANOPY Trial Pamela Hawn, PharmD, Senior Director of Medical AffairsOctober 19 (12:15 – 1:30pm PT/3:15 – 4:30pm ET) “We are excited to share these data with the infectious disease community as the threat from COVID-19 persists and has a disproportionate impact on individuals with compromised immune systems who may not be fully protected by vaccines,” said Robert Allen, Ph.D., Chief Scientific Officer at Invivyd. A copy of the posters and presentation will be available on the company’s website following the conference. About PEMGARDA PEMGARDA™ (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab, Invivyd’s investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in a global Phase 2/3 clinical trial for the prevention and treatment of COVID-19. PEMGARDA has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells. PEMGARDA injection (4500 mg), for intravenous use is an investigational mAb that has not been approved, but has been authorized for emergency use by the U.S. FDA under an EUA for the pre-exposure prophylaxis (preven...